{"id":"finasteride","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Decreased Libido","drugRate":"1.8%","severity":"common","organSystem":""},{"effect":"Erectile Dysfunction","drugRate":"1.3%","severity":"common","organSystem":""},{"effect":"Ejaculation Disorder","drugRate":"1.2%","severity":"common","organSystem":""},{"effect":"Decreased Volume of Ejaculate","drugRate":"0.8%","severity":"common","organSystem":""},{"effect":"Discontinuation due to drug-related sexual adverse experiences","drugRate":"1.2%","severity":"common","organSystem":""}],"contraindications":["Breast Carcinoma in Males","Breastfeeding (mother)","Disease of liver","High-Grade Prostate Cancer","Pregnancy, function"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"approved","trials":["NCT01643629","NCT00130767","NCT01534351","NCT06001619","NCT06601205","NCT07076706","NCT01052870","NCT00690950","NCT00564460","NCT06282731","NCT01585441","NCT06590779","NCT00438464","NCT02146937","NCT07038941","NCT04594018","NCT01703520","NCT00003323","NCT06826001","NCT02548117","NCT07435012","NCT00650377","NCT01435954","NCT02248701","NCT00396175","NCT01390870","NCT04032067","NCT00127179","NCT00064649","NCT01296672","NCT01376258","NCT05893849","NCT00542243","NCT01381510","NCT02502669","NCT01231607","NCT01264289","NCT01227993","NCT01923090","NCT06944145","NCT00837252","NCT00870480","NCT00835666","NCT01133457","NCT02824380","NCT04945226","NCT00736645","NCT00759135","NCT02213107","NCT00382356"],"aliases":["Propecia","Proscar"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.0478/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$17","description":"FINASTERIDE 1 MG TABLET","retrievedDate":"2026-04-07"}],"allNames":"propecia","offLabel":[],"timeline":[],"aiSummary":"Finasteride is a 5-alpha-reductase inhibitor developed by Merck, approved in 1992. Marketed as Proscar (BPH) and Propecia (hair loss). Available generically.","brandName":"Propecia","companyId":"merck","ecosystem":[],"mechanism":{"target":"3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 1, Cytochrome P450 2C19, Cytochrome P450 2C9","novelty":"","modality":"Small molecule","drugClass":"5-alpha-reductase inhibitor","explanation":"Finasteride blocks the conversion of testosterone to DHT, the androgen primarily responsible for prostate growth and androgenetic alopecia. At 5mg (Proscar) it shrinks the prostate in BPH; at 1mg (Propecia) it treats male pattern baldness. Teratogenic — women who are or may become pregnant must not handle crushed tablets.","oneSentence":"Selective type II 5-alpha-reductase inhibitor that blocks conversion of testosterone to dihydrotestosterone (DHT), treating BPH and male pattern hair loss.","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Merck & Co.","competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"},{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"finasteride","indications":{"approved":[{"name":"Benign prostatic hyperplasia","diseaseId":"benign-prostatic-hyperplasia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Male Patterned Baldness","diseaseId":"male-patterned-baldness","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01643629","phase":"Phase 1","title":"A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic A","status":"UNKNOWN","sponsor":"Kasiak Research Pvt. Ltd.","isPivotal":false,"enrollment":20,"indication":"Androgenetic Alopecia","completionDate":"2012-11"},{"nctId":"NCT00130767","phase":"Phase 4","title":"Kinetics of the Finasteride Prostate Induced Apoptosis","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","isPivotal":false,"enrollment":90,"indication":"Benign Prostatic Hyperplasia","completionDate":""},{"nctId":"NCT01534351","phase":"Phase 3","title":"A Phase III, Randomized Clinical Trial to Study the Safety and Efficacy of MK-906 (Finasteride) and Tamsulosin Administered Either Alone or Concomitantly in Patients With Benign Prostatic Hyperplasia ","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","isPivotal":true,"enrollment":1,"indication":"Benign Prostatic Hyperplasia","completionDate":"2013-11-18"},{"nctId":"NCT06001619","phase":"Phase 4","title":"Prostate Medication, Metabolism and Gut Microbiota","status":"RECRUITING","sponsor":"Turku University Hospital","isPivotal":false,"enrollment":100,"indication":"Prostatic Hyperplasia, Prostate Cancer","completionDate":"2026-12-31"},{"nctId":"NCT06601205","phase":"Phase 2","title":"A Randomized, Phase IIB, Double Blind, Placebo Controlled, Multicenter, Pre-surgical, Window-of-opportunity Trial of Finasteride Vs. Low-dose Flutamide Vs. Placebo in Prostate Cancer (2F Trial)","status":"COMPLETED","sponsor":"Ente Ospedaliero Ospedali Galliera","isPivotal":true,"enrollment":125,"indication":"Prostate Cancer, Prostatic Intraepithelial Neoplasia","completionDate":"2017-06-16"},{"nctId":"NCT07076706","phase":"Phase 2","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Beijing Dayspring Pharmaceutical Technology Co., Ltd","isPivotal":false,"enrollment":110,"indication":"Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)","completionDate":"2025-09-23"},{"nctId":"NCT01052870","phase":"Phase 1","title":"Study Evaluating the Association of CAG Repeat Polymorphisms and Finasteride Response in Women With Androgenetic Alopecia","status":"COMPLETED","sponsor":"HairDx, LLC","isPivotal":false,"enrollment":12,"indication":"Androgenetic Alopecia","completionDate":"2009-12"},{"nctId":"NCT00690950","phase":"Phase 4","title":"Switch Study: Are There Any Measurable Differences When Switching Patients on Finasteride Therapy to Dutasteride?","status":"UNKNOWN","sponsor":"Urologic Consultants of Southeastern PA","isPivotal":false,"enrollment":50,"indication":"Benign Prostatic Hyperplasia","completionDate":""},{"nctId":"NCT00564460","phase":"Phase 3","title":"On Label, Randomized, Double-Blind, Placebo-Controlled Trial of Preoperative Finasteride in Patients Undergoing Transurethral Resection of the Prostate (TURP)","status":"WITHDRAWN","sponsor":"University of Alberta","isPivotal":true,"enrollment":0,"indication":"Benign Prostatic Hyperplasia","completionDate":"2011-02"},{"nctId":"NCT06282731","phase":"EARLY/Phase 1","title":"The Changes of Urine Growth Factors Level in Patients With Benigh Prostate Hyperplasia After Medical Treatment","status":"COMPLETED","sponsor":"En Chu Kong Hospital","isPivotal":false,"enrollment":74,"indication":"Benign Prostatic Hyperplasia","completionDate":"2017-04-27"},{"nctId":"NCT01585441","phase":"Phase 2","title":"Phase II, Randomized, Placebo-Controlled Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy","status":"TERMINATED","sponsor":"National Eye Institute (NEI)","isPivotal":false,"enrollment":6,"indication":"Retinal Disease","completionDate":"2013-12"},{"nctId":"NCT06590779","phase":"NA","title":"Evaluation of the Benefits of a Cosmetic Anti-hair Loss Lotion Applied in Combination With Finasteride in Male Subjects With Hair Loss: Investigator-blinded, Randomized, Multi-center Study Performed U","status":"NOT_YET_RECRUITING","sponsor":"Cosmetique Active International","isPivotal":false,"enrollment":140,"indication":"Androgenetic Alopecia","completionDate":"2026-05-02"},{"nctId":"NCT00438464","phase":"Phase 2","title":"A Randomized Controlled Trial Evaluating the Tissue Effects of Preoperative Finasteride Versus Placebo for Patients With Clinically Organ-Confined Prostate Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","isPivotal":false,"enrollment":204,"indication":"Adenocarcinoma of the Prostate, Stage II Prostate Cancer","completionDate":"2012-04"},{"nctId":"NCT02146937","phase":"Phase 2","title":"A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","isPivotal":false,"enrollment":0,"indication":"Detectable Prostate Nodules","completionDate":"2015-03"},{"nctId":"NCT07038941","phase":"Phase 1","title":"A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial of Single and Multiple Doses of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Beijing Dayspring Pharmaceutical Technology Co., Ltd","isPivotal":false,"enrollment":44,"indication":"Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)","completionDate":"2024-06-02"},{"nctId":"NCT04594018","phase":"Phase 3","title":"National, Multicentre, Randomized, Double-blind, Double-dummy Phase III Clinical Trial to Evaluate the Efficacy and Safety of Finlândia Hair Lotion Association in the Treatment of Androgenetic Alopeci","status":"RECRUITING","sponsor":"EMS","isPivotal":true,"enrollment":190,"indication":"Androgenetic Alopecia","completionDate":"2027-09"},{"nctId":"NCT01703520","phase":"N/A","title":"Finasteride and Male Breast Cancer - A Register-Based Nested Case-Control Study in Denmark, Finland, Norway, and Sweden","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":false,"enrollment":575216,"indication":"Male Breast Cancer","completionDate":"2017-11-30"},{"nctId":"NCT00003323","phase":"Phase 2","title":"A Phase II Trial of Potency-Sparing Hormonal Therapy in Patients With Elevated Serum PSA After Radiation Therapy or Radical Prostatectomy for Prostate Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","isPivotal":false,"enrollment":101,"indication":"Prostate Cancer, Sexual Dysfunction and Infertility","completionDate":"2010-03"},{"nctId":"NCT06826001","phase":"Phase 2","title":"COMPARISON OF EFFICACY OF TOPICAL FINESTERIDE VERSUS TOPICAL MINOXIDAL IN TREATMENT OF ANDROGENETIC ALOPECIA","status":"NOT_YET_RECRUITING","sponsor":"Sheikh Zayed Medical College","isPivotal":false,"enrollment":190,"indication":"Androgenetic Alopecia","completionDate":"2025-07"},{"nctId":"NCT02548117","phase":"Phase 3","title":"H-36371: Finasteride as a Method of Managing Testosterone-Induced Erythrocytosis","status":"WITHDRAWN","sponsor":"Baylor College of Medicine","isPivotal":true,"enrollment":0,"indication":"ERYTHROCYTOSIS","completionDate":"2016-02"},{"nctId":"NCT07435012","phase":"Phase 3","title":"Phase III, Parallel Design, Triple-Blind, Randomized, Multicenter Clinical Trial to Evaluate Safety & Efficacy of TH07 Topical Treatment in Male Patients With Androgenic Alopecia.","status":"RECRUITING","sponsor":"Triple Hair Inc","isPivotal":true,"enrollment":420,"indication":"Androgenic Alopecia","completionDate":"2028-04"},{"nctId":"NCT00650377","phase":"Phase 1","title":"Single-Dose Food In Vivo Bioequivalence Study of Finasteride Tablets (5 mg; Mylan) to Proscar® Tablets (5 mg; Merck) in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","isPivotal":false,"enrollment":30,"indication":"Healthy","completionDate":"2004-10"},{"nctId":"NCT01435954","phase":"N/A","title":"Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":13551,"indication":"Benign Prostatic Hyperplasia","completionDate":"2011-03"},{"nctId":"NCT02248701","phase":"Phase 2","title":"Higher-Than-Replacement Testosterone Plus Finasteride Treatment After SCI","status":"TERMINATED","sponsor":"VA Office of Research and Development","isPivotal":false,"enrollment":33,"indication":"Spinal Cord Injury, Spinal Cord Injuries","completionDate":"2021-08-13"},{"nctId":"NCT00396175","phase":"Phase 3","title":"A Double-Blind, Placebo-Controlled, Multicenter Study To Examine the Effects of Finasteride 1 MG on Serum Prostate-Specific Antigen in Men With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":355,"indication":"Androgenetic Alopecia","completionDate":""},{"nctId":"NCT01390870","phase":"N/A","title":"Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":400,"indication":"Prostatic Hyperplasia","completionDate":"2010-09"},{"nctId":"NCT04032067","phase":"Phase 3","title":"A Randomized, Active-Controlled, Double-Blind, Parallel Design, Multi-Center, Phase III Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)","status":"COMPLETED","sponsor":"GemVax & Kael","isPivotal":true,"enrollment":423,"indication":"Benign Prostatic Hyperplasia (BPH)","completionDate":"2022-03-17"},{"nctId":"NCT00127179","phase":"Phase 3","title":"MK0906 Phase III Double-Blind Comparative Study - Benign Prostate Hyperplasia","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":600,"indication":"Benign Prostatic Hyperplasia","completionDate":"2005-07-25"},{"nctId":"NCT00064649","phase":"Phase 3","title":"Minimally Invasive Surgical Therapy Consortium for Benign Prostatic Hyperplasia","status":"TERMINATED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","isPivotal":true,"enrollment":49,"indication":"Benign Prostatic Hyperplasia","completionDate":"2006-06"},{"nctId":"NCT01296672","phase":"Phase 4","title":"Improving Prostate Biopsy Efficiency: The Finasteride Challenge Test","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","isPivotal":false,"enrollment":383,"indication":"Prostate Cancer","completionDate":"2017-01"},{"nctId":"NCT01376258","phase":"N/A","title":"Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":28903,"indication":"Prostatic Hyperplasia","completionDate":"2010-12"},{"nctId":"NCT05893849","phase":"N/A","title":"A Single Center, Open Label Study of Pharmacokinetics of Clinical Probes and Characteristics of Endogenous Biomarker for Drug-metabolizing Enzymes and Transporters in Chinese Older Adults","status":"UNKNOWN","sponsor":"Peking University Third Hospital","isPivotal":false,"enrollment":624,"indication":"Aging","completionDate":"2024-04"},{"nctId":"NCT00542243","phase":"Phase 3","title":"A Phase III, Randomized, Double-Blind, Placebo Controlled Trial of PROSCAR in Men With Initial Negative Prostate Biopsies","status":"COMPLETED","sponsor":"University Health Network, Toronto","isPivotal":true,"enrollment":19,"indication":"Enlarged Prostate","completionDate":"2012-12"},{"nctId":"NCT01381510","phase":"N/A","title":"Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":false,"enrollment":54459,"indication":"Prostatic Hyperplasia","completionDate":"2010-08"},{"nctId":"NCT02502669","phase":"Phase 2","title":"A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne","status":"COMPLETED","sponsor":"Elorac, Inc.","isPivotal":false,"enrollment":106,"indication":"NODULOCYSTIC ACNE","completionDate":"2017-06-06"},{"nctId":"NCT01231607","phase":"Phase 3","title":"A Study of the Efficacy and Safety of Multiple Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects With Androgenetic Alopecia","status":"COMPLETED","sponsor":"GlaxoSmithKline","isPivotal":true,"enrollment":917,"indication":"Androgenetic Alopecia","completionDate":"2012-02-28"},{"nctId":"NCT01264289","phase":"Phase 1","title":"A Randomized, Single-dose, Two-treatment, Two-way, Crossover Bioequivalence Study of Finasteride 5 mg Tablets (Dr. Reddy's Laboratories Limited) With the Reference Formulation PROSCAR® 5 mg Tablet (Me","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","isPivotal":false,"enrollment":26,"indication":"Healthy","completionDate":"2006-11"},{"nctId":"NCT01227993","phase":"Phase 1","title":"Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","isPivotal":false,"enrollment":3,"indication":"Retinal Disease","completionDate":"2013-06"},{"nctId":"NCT01923090","phase":"Phase 2","title":"An Open Label Study of 5α-reductase Inhibition on the Regulation of Insulin Action and Metabolic Phenotype in Healthy Volunteers.","status":"UNKNOWN","sponsor":"University of Birmingham","isPivotal":false,"enrollment":12,"indication":"Healthy Volunteers","completionDate":"2013-10"},{"nctId":"NCT06944145","phase":"Phase 2","title":"A Phase 2b Randomized, Single-Center, Double Blind, Placebo Controlled, 2-Arm Study to Investigate Orally Administered Combination Therapies (5-alpha Reductase Inhibitor + Raloxifene) Compared With Mo","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","isPivotal":false,"enrollment":242,"indication":"BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms","completionDate":"2030-08-31"},{"nctId":"NCT00837252","phase":"Phase 1","title":"Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","isPivotal":false,"enrollment":5,"indication":"Retinal Disease","completionDate":"2010-04"},{"nctId":"NCT00870480","phase":"Phase 1","title":"Randomized, 2-Way Crossover Bioequivalence Study Finasteride 5 mg Tablet and Proscar Administrated as 1 x 5 mg Tablet in Healthy Subjects Under Fasting Conditions.","status":"COMPLETED","sponsor":"Actavis Inc.","isPivotal":false,"enrollment":26,"indication":"Healthy","completionDate":"2004-11"},{"nctId":"NCT00835666","phase":"Phase 1","title":"A Relative Bioavailability Study of Finasteride 5 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","isPivotal":false,"enrollment":32,"indication":"Healthy","completionDate":"2002-06"},{"nctId":"NCT01133457","phase":"Phase 1","title":"Comparative,Randomized,Single-dose,2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories Limited Finasteride Tablets 1 mg and Merck & Co., Propecia in Healthy Adult Males Under Fed Conditio","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","isPivotal":false,"enrollment":24,"indication":"Healthy","completionDate":"2002-05"},{"nctId":"NCT02824380","phase":"Phase 1","title":"","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","isPivotal":false,"enrollment":14,"indication":"Androgenic Alopecia","completionDate":"2016-10"},{"nctId":"NCT04945226","phase":"Phase 1","title":"A Randomized, Open-Label, Exploratory, Pharmacokinetic, Sequential Single Ascending Dose Study of IVL3001 Versus Propecia (Finasteride) Tablets in Healthy Adult Participants","status":"COMPLETED","sponsor":"Inventage Lab., Inc.","isPivotal":false,"enrollment":40,"indication":"Androgenetic Alopecia","completionDate":"2022-02-08"},{"nctId":"NCT00736645","phase":"Phase 2","title":"A Randomized, Double Blind, Placebo Controlled Clinical Trial of L-SeMet Supplementation and Finasteride Treatment of Patients With Prostate Cancer Prior to Robotic Prostatectomy/Brachytherapy","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","isPivotal":false,"enrollment":55,"indication":"Prostate Cancer","completionDate":"2012-12"},{"nctId":"NCT00759135","phase":"Phase 2","title":"Phase 2 Multicenter Randomized Two Dose Level and Non-Inferiority Clinical Evaluation of Transrectal Administration of NX-1207 for the Treatment of BPH","status":"COMPLETED","sponsor":"Nymox Corporation","isPivotal":false,"enrollment":85,"indication":"Benign Prostatic Hyperplasia (BPH), Enlarged Prostate","completionDate":"2008-05"},{"nctId":"NCT02213107","phase":"Phase 2","title":"A Phase II Study of Enzalutamide Plus Dutasteride/Finasteride as First Line Treatment for Vulnerable Patients ≥ 65 Years With Systemic Prostate Cancer","status":"COMPLETED","sponsor":"University of Rochester","isPivotal":false,"enrollment":43,"indication":"Prostate Cancer","completionDate":"2023-10-31"},{"nctId":"NCT00382356","phase":"NA","title":"A Pilot Investigation of Dutasteride (Avodart) After Failure of Finasteride (Proscar) In the Management of Symptomatic Prostatic Enlargement/Hypertrophy (BPE/H)","status":"COMPLETED","sponsor":"North Florida/South Georgia Veterans Health System","isPivotal":false,"enrollment":20,"indication":"Benign Prostatic Hypertrophy","completionDate":"2009-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Oral","frequency":"Once daily","formulation":"Tablet"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Urology"],"biosimilarFilings":[],"firstApprovalDate":"1992-06-19","companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}